Helsinki, June 11, 2014 - NASDAQ OMX (NASDAQ: NDAQ) announced that trading in Herantis Pharma Plc (HRTIS) shares commenced today on First North Finland. The company belongs to the Health Care sector. First North Finland is a Multilateral Trading Facility (MTF) aimed towards emerging growth companies and has been operated by NASDAQ OMX Helsinki since April 4, 2011.
Herantis Pharma Plc is a pharmaceutical company specialised in advancing scientific research into clinical research aiming at developing new drugs. The company focuses on diseases with an unmet clinical need. These diseases include for example dry eye syndrome, Parkinson’s disease, and secondary lymphedema. For more information, visit www.herantis.com
Pekka Simula, CEO of Herantis Pharma Plc, commented: ”The First North listing was an optimal way to raise funding for our product pipeline. It’s been 14 years since the last IPO of a drug development company in Finland - we hope that our success encourages others to follow.”
Lauri Rosendahl, President of NASDAQ OMX Helsinki, said: “We welcome Herantis Pharma Plc to First North and to our Health Care sector. Herantis Pharma Plc is a great example of an innovative growth company that is utilizing our First North platform to achieve increased investor exposure and awareness. We look forward to a long-standing partnership with the company and its shareholders.”
Herantis Pharma Plc has appointed UB Capital Oy as Certified Adviser.
About First North
First North is regulated as a multilateral trading facility, operated by the different exchanges within NASDAQ OMX Nordic. It does not have the legal status as an EU-regulated market. Companies at First North are subject to the rules of First North and not the legal requirements for admission to trading on a regulated market. The risk in such an investment may be higher than on the main market.
About NASDAQ OMX Group
NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, NASDAQ OMX enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets. As the creator of the world’s first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. NASDAQ OMX is home to more than 3,400 listed companies with a market value of over $8.5 trillion and more than 10,000 corporate clients. NASDAQ OMX Nordic is not a legal entity but describes the common offering from NASDAQ OMX exchanges in Helsinki, Copenhagen, Stockholm and Iceland. To learn more, visit www.nasdaqomx.com.
Cautionary Note Regarding Forward-Looking Statements
Information set forth in this communication contains forward-looking statements that involve a number of risks and uncertainties. NASDAQ OMX cautions readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information. Such forward-looking statements include, but are not limited to, statements about our capital return initiatives. Forward-looking statements involve a number of risks, uncertainties or other factors beyond NASDAQ OMX’s control. These factors include, but are not limited to, NASDAQ OMX’s ability to implement its strategic initiatives, economic, political and market conditions and fluctuations, government and industry regulation, interest rate risk, U.S. and global competition, and other factors detailed in NASDAQ OMX’s filings with the U.S. Securities and Exchange Commission, including its annual reports on Form 10-K and quarterly reports on Form 10-Q which are available on NASDAQ OMX’s website at http://www.nasdaqomx.com and the SEC’s website at www.sec.gov. NASDAQ OMX undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
MEDIA RELATIONS CONTACT:
tel. +358 (0)9 6166 7274